Allogene Therapeutics, Inc. (ALLO) Spending and interest coverage
- R&D / revenue · 12 months: Value 2640.52%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 808.02%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 2640.52% | Research and development expense / revenue. Period ending 2026-06-30. $122.52M ÷ $4.64M × 100 ≈ 2640.52% |
| Stock-based compensation / revenue · 12 months | 808.02% | Share-based compensation / revenue. Period ending 2026-06-30. $37.49M ÷ $4.64M × 100 ≈ 808.02% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 122.52M USD | Research and Development Expense |
| Revenue | 4.64M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 37.49M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -180.32M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $122.52M | $4.64M | $37.49M | $-180.32M | (m) | 2640.52% | 808.02% | (m) | (m) |
| 2026-03-31 | $131.96M | (m) | $33.74M | $-190.22M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $150.15M | $0.00 | $37.64M | $-209.31M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $166.49M | $0.00 | $42.38M | $-227.40M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $180.04M | $0.00 | $47.12M | $-254.27M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $190.24M | $0.00 | $51.99M | $-268.89M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $192.30M | $22.00K | $51.74M | $-273.20M | (m) | 874086.36% | 235195.45% | (m) | (m) |
| 2024-09-30 | $201.99M | $43.00K | $54.10M | $-297.82M | (m) | 469739.53% | 125820.93% | (m) | (m) |
| 2024-06-30 | $203.25M | $65.00K | $56.07M | $-289.04M | (m) | 312695.38% | 86261.54% | (m) | (m) |
| 2024-03-31 | $214.94M | $87.00K | $59.10M | $-298.15M | (m) | 247051.72% | 67936.78% | (m) | (m) |
| 2023-12-31 | $242.91M | $95.00K | $65.95M | $-327.74M | (m) | 255698.95% | 69422.11% | (m) | (m) |
| 2023-09-30 | $263.67M | $186.00K | $67.96M | $-338.94M | (m) | 141759.14% | 36539.78% | (m) | (m) |
| 2023-06-30 | $281.34M | $192.00K | $73.76M | $-358.45M | (m) | 146529.17% | 38415.63% | (m) | (m) |
| 2023-03-31 | $276.47M | $234.00K | $80.06M | $-354.53M | (m) | 118149.15% | 34211.54% | (m) | (m) |
| 2022-12-31 | $256.39M | $243.00K | $83.60M | $-335.45M | (m) | 105509.05% | 34403.29% | (m) | (m) |
| 2022-09-30 | $234.95M | $247.00K | $88.39M | $-312.97M | (m) | 95121.86% | 35785.43% | (m) | (m) |
| 2022-06-30 | $230.03M | $247.00K | $88.10M | $-308.15M | (m) | 93129.55% | 35667.21% | (m) | (m) |
| 2022-03-31 | $225.15M | $205.00K | $86.34M | $-302.58M | (m) | 109828.78% | 42117.56% | (m) | (m) |
| 2021-12-31 | $220.18M | $38.49M | $80.82M | $-255.79M | (m) | 572.05% | 209.98% | (m) | (m) |
| 2021-09-30 | $218.42M | (m) | $75.23M | $-251.26M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $211.12M | (m) | $72.20M | $-241.63M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $206.13M | (m) | $67.84M | $-233.76M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $192.99M | (m) | $65.26M | $-258.24M | $0.00 | (m) | (m) | (m) | Reported |
| 2020-09-30 | $190.12M | (m) | $62.68M | $-253.46M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $178.69M | (m) | $57.69M | $-240.43M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $163.17M | (m) | $52.41M | $-223.23M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $144.53M | (m) | $46.06M | $-202.01M | $0.00 | (m) | (m) | (m) | Reported |
| 2019-09-30 | $113.68M | (m) | $38.06M | $-170.48M | $0.00 | (m) | (m) | (m) | Reported |
| 2019-06-30 | $84.55M | (m) | $29.86M | $-137.66M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | $26.43M | $-226.71M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $151.86M | (m) | $18.57M | $-192.84M | $3.36M | (m) | (m) | -57.43× | Reported |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |